US-based Baptist Health South Florida has partnered with healthcare data and analytics company Cota to help build precision medicine and research programmes at the new Miami Cancer Institute.
The institute will use Cota’s oncology analytics suite to recognise clinical variances, provide clinical decision support, and optimise billing in both fee-for-service and value-based payment models.
The suite includes the Cota Nodal Address (CNA), a precision patient classification system, and Cota Real-World Evidence (RWE), a collection of oncology patient knowledge base.
Miami Cancer Institute founding CEO and executive medical director Michael Zinner said: “Miami Cancer Institute is committed to combining the latest technology and innovation to enable personalized medicine in cancer care.
“That is why we selected Cota, a market leader in data and analytics. By using their Provider Solution and CNA we’ll be able to generate critical insights from our data to continually improve the quality of care we deliver to our patients.”
The institute is improving patient access to the latest cancer treatment advances through its role in the Memorial Sloan Kettering Cancer Alliance (MSK).
Recently, Cota announced a partnership with MSK in a bid to improve patient care.
Cota chief medical officer Andrew Norden added: “The benefits of leveraging the CNA will result in reducing unwarranted variation in treatments, costs and outcomes and lead to treatment standardization and notable operational improvement on a practice and physician level, setting Miami Cancer Institute apart from other providers.
“The use of Cota through the lens of the CNA enables physicians and other health care professionals to deliver care resulting in optimal clinical outcomes for every individual patient and to reduce the total cost of care for the population being served.”